Nostrum, VCU sign license agreement to develop inhaled dapsone for respiratory diseases
22:47 EDT 16 Aug 2012 | The Medical News
Virginia Commonwealth University and Nostrum Pharmaceuticals, LLC, are pleased to announce the signing of a license agreement for the development of inhaled dapsone for the treatment of respiratory diseases.
Original Article: Nostrum, VCU sign license agreement to develop inhaled dapsone for respiratory diseases
More From BioPortfolio on "Nostrum, VCU sign license agreement to develop inhaled dapsone for respiratory diseases"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
